| URL | https://www.pharmaceutical-technology.com/news/gsk |
| Source | Pharmaceutical Technology |
| Date Published | 09/26/2019 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | GlaxoSmithKline |
| Parent company | GlaxoSmithKline |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2019 |
| Capital investment ($): | 120 |
| Country(ies) from which reshored: | United Kingdom |
| City reshored to: | King of Prussia |
| State(s) reshored to: | PA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | specialty medicines |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Customer responsiveness improvement, Customization/Flexibility, Infrastructure, Image/brand, Lead time/Time to market, Proximity to customers/market, Skilled workforce availability/training, Other, expansion |